Citigroup
KRTX

Citigroup’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Citigroup’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$6.33M – 5914
2023
Q4 		$6.33M Buy
20,000
+3,900
+24% +$758K ﹤0.01% 1451
2023
Q3 		$2.72M Sell
16,100
-3,900
-20% -$733K ﹤0.01% 1789
2023
Q2 		$4.34M Buy
+20,000
New +$4.28M ﹤0.01% 1585

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Citigroup's KRTX Position: Q1 2024 in Review

Citigroup sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 141,738 shares — an estimated $44.9M sold.

Citigroup first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $44.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Citigroup reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citigroup sold 141,738 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $44.9M.
  • Citigroup first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Citigroup's Karuna Therapeutics, Inc. Common Stock position peaked at $44.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.